ALK and non-small cell lung carcinoma: ,26 Second- and third-generation ALK TKIs (alectinib, brigatinib, ceritinib, and lorlatinib) have efficacy in the treatment of patients with ALK TKI-naive ALK+ NSCLC and have replaced crizotinib as recommended first-line treatments for patients with ALK+ NSCLC.11